|
Synonyms: ION 1166998 | ION-1166998 | ION373 | Zanvastro®
zilganersen is an approved drug
Compound class:
Nucleic acid
Comment: Zilganersen (ION373) is an 20-mer gapmer antisense oligonucleotide (ASO) that is designed to reduce synthesis of glial fibrillary acidic protein (GFAP) in the brain of patients with Alexander disease.
Chemically it has a phosphorothioate/phosphate backbone, modified 2'-O-methoxyethyl ribose and deoxyribose sugars and base substitutions. Full sequence is: all-P-ambo-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)adenylyl-(3'→5')-2'-O-(2-methoxyethyl)guanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'→5')-2'-O-(2-methoxyethyl)adenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-O-(2-methoxyethyl)adenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidine |
Classification ![]() |
|
| Compound class | Nucleic acid |
| Compound subclass | Antisense oligonucleotide (ASO) |
| Target | glial fibrillary acidic protein (GFAP) pre-mRNA |
| Approved drug? | Yes. US FDA (2026) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 11915 | zilganersen |
Synonyms ![]() |
| ION 1166998 | ION-1166998 | ION373 | Zanvastro® |
Database Links ![]() |
|
| CAS Registry No. | 2305355-56-8 (source: WHO INN record) |
| DrugBank Ligand | DB18161 |
| Search PubMed clinical trials | zilganersen |
| Search PubMed titles | zilganersen |
| Search PubMed titles/abstracts | zilganersen |